The molecule was created by chemist Corey Hopkins, PhD, at the University of Nebraska Medical Center College of Pharmacy. UNeMed, UNMC's technology transfer office, helped establish Goldenrod in 2023 and put the licence in place. In June 2026 the company closed a $6.5M seed round led by Ataxia Ventures and an affiliate of Fannin Partners to complete the studies needed for clinical trials planned for 2027.